Recent news

[CLOVES syndrome] : The U.S. FDA approves Alpelisib based on a French study

[CLOVES syndrome] : The U.S. FDA approves Alpelisib based on a French study

AP-HP, Inserm and Université Paris Cité extend their congratulations to Professor Guillaume Canaud’s teams at Necker-Enfants Malades Hospital (AP-HP), Necker-Enfants Malades Institute (INEM), Inserm, Institut Imagine and Université Paris Cité for their work on alpelisib (BYL719), approved by the US Food and Drug Administration (FDA). Lire la suite [CLOVES syndrome] : The U.S. FDA approves Alpelisib based on a French study